|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Clarus Therapeutics Announces Completion of $8 Million Series C Financing Round
11/27/2007 10:48:23 AM
NORTHBROOK, Ill.--(BUSINESS WIRE)--Clarus Therapeutics, Inc., a private firm focused on the development of an oral testosterone replacement product, today announced the close of an $8 million Series C financing. H.I.G. Ventures led the round and was joined by Thomas, McNerney & Partners – the sole institutional investor in the Series A and B rounds. To date, Clarus has secured venture funding commitments totaling $15 million. In conjunction with the Series C financing, Bruce Robertson, Ph.D. and Michael Wasserman, Ph.D. of H.I.G. Ventures will join Alex Zisson and James Thomas from Thomas, McNerney & Partners and President and CEO Robert Dudley, Ph.D. on Clarus’s board of directors.
|
|
|
|
|
|
|
|
|
|
|